Immune-mediated myositis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:14:29 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Immune-mediated myositis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases https://clinicaltrials.eu/trial/study-on-the-effects-of-rapcabtagene-autoleucel-and-drug-combination-for-patients-with-severe-refractory-inflammatory-muscle-diseases/ Wed, 29 Apr 2026 15:03:09 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-rapcabtagene-autoleucel-and-drug-combination-for-patients-with-severe-refractory-inflammatory-muscle-diseases/ This clinical trial is focused on studying the effects of a new treatment called YTB323 in people with severe inflammatory muscle diseases known as idiopathic inflammatory myopathies (IIM). These are conditions where the body’s immune system mistakenly attacks its own muscles, causing inflammation and weakness. The main treatment being tested is rapcabtagene autoleucel, which is a type of cell therapy that uses the patient’s own immune cells, modified to better fight the disease. This treatment is given as a single infusion directly into the bloodstream.

The purpose of the study is to see if rapcabtagene autoleucel can provide better results compared to other treatments chosen by doctors. Participants will receive either the new treatment or a different treatment selected by their doctor. The study will last for about a year, during which participants will be monitored to see if there is an improvement in their condition. The study will also look at the safety of the treatment and any side effects that may occur.

In addition to YTB323, other medications that may be used in the study include rituximab, mycophenolic acid, tacrolimus, tocilizumab, fludarabine phosphate, and cyclophosphamide. These medications are commonly used to manage symptoms and control the immune system in people with inflammatory muscle diseases. The study aims to provide valuable information on how effective and safe these treatments are for people with severe forms of these conditions.

]]> Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG https://clinicaltrials.eu/trial/study-on-upadacitinib-for-patients-with-idiopathic-inflammatory-myopathies-after-stopping-ivig/ Wed, 29 Apr 2026 14:58:28 +0000 https://clinicaltrials.eu/trial/study-on-upadacitinib-for-patients-with-idiopathic-inflammatory-myopathies-after-stopping-ivig/ This clinical trial is focused on studying a group of diseases known as idiopathic inflammatory myopathies. These diseases include polymyositis, dermatomyositis, antisynthetase syndrome, overlap myositis, and immune-mediated necrotizing myopathy. These conditions are characterized by inflammation of the muscles, which can lead to muscle weakness and other symptoms. The trial will evaluate the effectiveness and safety of a medication called Upadacitinib, also known by its code name ABT-494. This medication is taken orally in the form of prolonged-release tablets, which means it is designed to release the active ingredient slowly over time.

The purpose of the study is to assess whether patients can maintain stable disease activity without the need for intravenous immunoglobulins (IVIG), a common treatment for these conditions. Participants in the study will be randomly assigned to receive either Upadacitinib or a placebo, which is a substance with no active medication. The study will last for a period of 20 weeks, during which the participants’ health and disease activity will be closely monitored. The main goal is to see if patients can remain stable without IVIG by the 16th week of the study.

Throughout the trial, various aspects of the participants’ health will be evaluated, including muscle strength, quality of life, and any side effects experienced. The study will also compare the time it takes for symptoms to worsen between those taking Upadacitinib and those taking the placebo. This research aims to provide valuable insights into the potential of Upadacitinib as a treatment option for individuals with idiopathic inflammatory myopathies, potentially reducing the need for IVIG and improving overall management of these conditions.

]]>